Concord Drugs Limited is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 52 | 45 | 45 | 79 |
| EBITDA (ex other income) | 5 | 4 | 4 | 5 |
| margin % | 8.8 | 9.0 | 9.1 | 5.7 |
| Owners' profit | 0 | 0 | 0 | 1 |
| EPS, as reported (₹) | 1.06 | 0.47 | 0.34 | 0.95 |
| ROE % · ROCE % | 3.1 · 8.1 | 1.4 · 6.7 | 1.0 · 7.0 | 2.2 · 5.9 |
| Debt / equity (x) | 0.51 | 0.49 | 0.50 | 0.28 |
| Cash from operations | 2 | 1 | 4 | (7) |
| Capex | (1) | (1) | (2) | (1) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 11 | 10 | 14 | 10 | 17 | 38 | 21 |
| Profit before tax | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| EPS (₹) | 0.04 | 0.23 | 0.04 | 0.12 | 0.31 | 0.16 | 0.47 | 0.85 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · 31st AGM notice published; meeting on Sep 30, 2026 via VC | compliance | minimal | — | — |
| 7 Sept 2026 · Letter to members with Annual Report web link for FY 2025-26 | compliance | minimal | — | — |
| 7 Sept 2026 · Record date fixed at 23 Sep for Concord Drugs 31st AGM on 30 Sep 2026 | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Book Closure for AGM on 30 September 2026 | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Concord Drugs 31st AGM on Sept 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Notice of 31st AGM on 30 September 2026 at 09:30 AM | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Board approves 31st AGM notice, director re-appointments and auditor changes | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Q1 FY27 results: Revenue up 56% YoY, PAT jumps 10x to Rs 111 lakh | results | high | — | — |
| 10 Aug 2026 · Q1 FY27 results: revenue up 56 percent YoY at Rs 20.9 cr, PAT at Rs 1.1 cr | results | high | — | — |
| 3 Aug 2026 · Board meeting on 10 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 44.5 | 28.9 | 123 of 169 | 27% |
| P/B | 2.2 | 3.3 | 54 of 163 | 67% |
| ROCE | 2.7 | 10.8 | 140 of 183 | 24% |
| ROE | 2.2 | 10.4 | 137 of 171 | 20% |
| Debt / Equity | 0.3 | 0.1 | 118 of 171 | 31% |
| EBITDA margin | 10.9 | 17.5 | 118 of 165 | 29% |
| Revenue growth | 53.9 | 16.3 | 19 of 161 | 89% |
| Profit growth | 845.7 | 30.9 | 9 of 158 | 95% |
| Market cap | 105 | 839 | 134 of 182 | 27% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
